Overview

Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Status:
Withdrawn

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the efficacy of oral BG00012 as compared with placebo in pediatric subjects with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of this study are to evaluate the safety and tolerability of BG00012 and to compare the effect of BG00012 with placebo on additional clinical and radiological measures of disease activity.

Phase:

Phase 3

Details

Lead Sponsor:

Biogen

Treatments:

Dimethyl Fumarate